The Rise of Powerful Weight-Loss Drugs: Embracing GLP-1 Treatments

Report Issue

Please complete the required fields.

Your Name

Email

Reason (required)
This post contains broken linksPost has incorrect informationPost has spamCopyright IssueOther

Description

Submit

The sudden popularity of effective weight-loss drugs is scrambling the industry devoted to helping people shed pounds on their own, sending companies searching for ways to reinvent themselves.

Drugs like Wegovy and Mounjaro are transforming the weight-loss experience, introducing a dependable medical solution for people who need or want to be slimmer.

Jenny Craig is the latest company to be disrupted by the new class of weight-loss drugs, known as glucagon-like peptide-1 agonists, or GLP-1s. Jenny Craig announced in May that it was liquidating after four decades in operation. Then Nutrisystem owner Wellful said Wednesday that it was acquiring the brand and plans to revive it this fall. “We are watching the role pharmaceuticals play in the industry,” Wellful CEO Brandon Adcock tells Axios in an email, adding that “we are here to support the consumer wherever they are in their weight loss journey, recognizing the importance of learning proper nutrition. ”

Multiple other major weight-loss brands have taken steps in recent months to embrace GLP-1 treatments:

Digital health company Noom announced in May that it would launch a prescription service offering weight-loss drugs called Noom Med.

WeightWatchers announced in March that it was acquiring Sequence, a telehealth platform that provides patients with access to weight-loss drugs.

Other health companies not typically associated with weight-loss are exploring opportunities in this space, as well.